Objective:To observe the curative efficacy of Levoamlodipine Besylate (one of the medicine of calcium-channel blocker) and Telmisartan (an angiotensin Ⅱ receptor antagonist) on patients with left ventricular hypertrophy (LVH) caused by essential hypertension (EH), And contrast the role of the two effects, for clinical treatment provide the basis for hypertension.